Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC increased its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 40.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,168,057 shares of the life sciences company's stock after acquiring an additional 625,245 shares during the quarter. Janus Henderson Group PLC owned about 1.37% of Illumina worth $282,735,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ILMN. Empowered Funds LLC increased its stake in shares of Illumina by 1.7% during the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company's stock valued at $516,000 after buying an additional 66 shares during the period. Caprock Group LLC lifted its position in Illumina by 3.0% during the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company's stock valued at $376,000 after purchasing an additional 83 shares during the period. UMB Bank n.a. lifted its position in Illumina by 7.0% during the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company's stock valued at $140,000 after purchasing an additional 88 shares during the period. Integrated Advisors Network LLC lifted its position in Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company's stock valued at $585,000 after purchasing an additional 90 shares during the period. Finally, Moors & Cabot Inc. raised its position in Illumina by 1.7% in the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company's stock worth $759,000 after acquiring an additional 95 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Barclays increased their price target on shares of Illumina from $135.00 to $145.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. UBS Group increased their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Leerink Partners increased their price objective on shares of Illumina from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Thursday, October 17th. Canaccord Genuity Group increased their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a "hold" rating in a research note on Tuesday, November 5th. Finally, TD Cowen raised their target price on shares of Illumina from $166.00 to $177.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and an average target price of $164.00.

Illumina Price Performance

Illumina stock traded up $1.90 during midday trading on Wednesday, reaching $142.50. The company's stock had a trading volume of 1,410,359 shares, compared to its average volume of 2,021,730. The firm has a market capitalization of $22.60 billion, a PE ratio of -14.31 and a beta of 1.11. The stock's 50 day simple moving average is $142.74 and its 200 day simple moving average is $126.57. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.08 billion. During the same quarter in the previous year, the business earned $0.33 EPS. The company's revenue for the quarter was down 3.5% on a year-over-year basis. On average, equities research analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.